Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients

Journal of Hepatology

Volumn 54, Issue 1, 2011, Pages 41-47

  Vachon, Marie Louise C ^a   Factor, Stephanie H ^a   Branch, Andrea D ^a   Fiel, Maria Isabel ^a   Rodriguez Torres, Maribel ^b   Bräu, Norbert ^a,c   Sterling, Richard K ^d   Slim, Jihad ^e   Talal, Andrew H ^f   Dieterich, Douglas T ^a   Sulkowski, Mark S ^g  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Fundacion de Investigacion de Diego San Juan   (Puerto Rico)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e St Michael's Medical Center   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; Chronic; Hepatitis C virus; HIV; Insulin resistance; Pegylated interferon alfa 2a; Re treatment; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INFECTION; INSULIN RESISTANCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; RHABDOMYOLYSIS; STEATOSIS; SUICIDAL IDEATION; TREATMENT FAILURE;

ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; INTERFERON ALFA-2A; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE;

EID: 78649635332     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.06.025     Document Type: Article

References (36)

1. R. Weber, C.A. Sabin, N. Friis-Moller, P. Reiss, W.M. El-Sadr, and O. Kirk Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study Arch Intern Med 166 2006 1632 1641
2. D. Salmon-Ceron, C. Lewden, P. Morlat, S. Bevilacqua, E. Jougla, and F. Bonnet Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol J Hepatol 42 2005 799 805
3. M.L. Yu, S.M. Lin, W.L. Chuang, C.Y. Dai, J.H. Wang, and S.N. Lu A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan Antivir Ther 11 2006 985 994
4. J. Berenguer, J. Alvarez-Pellicer, P.M. Martin, J. Lopez-Aldeguer, M.A. Von-Wichmann, and C. Quereda Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 50 2009 407 413
5. Rodriguez-Torres M, Slim J, Bhatti Lea. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: Final results of the PARADIGM study. AASLD 60th; 2009 [abstract #1561].
6. M. Nunez, C. Miralles, M.A. Berdun, E. Losada, K. Aguirrebengoa, and A. Ocampo Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial AIDS Res Hum Retroviruses 23 2007 972 982
7. M. Laguno, J. Murillas, J.L. Blanco, E. Martinez, R. Miquel, and J.M. Sanchez-Tapias Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients AIDS 18 2004 F27 F36
8. R.P. Myers, Y. Benhamou, M. Bochet, V. Thibault, D. Mehri, and T. Poynard Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy AIDS 18 2004 75 79
9. M. Rodriguez-Torres, J.F. Rodriguez-Orengo, C.F. Rios-Bedoya, A. Fernandez-Carbia, E. Gonzalez-Lassalle, and R. Salgado-Mercado Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy J Clin Virol 38 2007 32 38
10. M. Crespo, J.A. Mira, J.A. Pineda, E. Van den Eynde, M.J. Rios-Villegas, and A. Collado Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen J Antimicrob Chemother. 62 2008 793 796
11. P. Labarga, E. Vispo, P. Barreiro, S. Rodriguez-Novoa, J. Pinilla, and J. Morello Rate and Predictors of Success in the Retreatment of Chronic Hepatitis C Virus in HIV/Hepatitis C Virus Coinfected Patients With Prior Nonresponse or Relapse J Acquir Immune Defic Syndr. 53 2010 364 368
12. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
13. Y. Shintani, H. Fujie, H. Miyoshi, T. Tsutsumi, K. Tsukamoto, and S. Kimura Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance Gastroenterology 126 2004 840 848
14. M. Romero-Gomez, M. Del Mar Viloria, R.J. Andrade, J. Salmeron, M. Diago, and C.M. Fernandez-Rodriguez Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 2005 636 641
15. K. Ishak, A. Baptista, L. Bianchi, F. Callea, J. De Groote, and F. Gudat Histological grading and staging of chronic hepatitis J Hepatol 22 1995 696 699
16. E.M. Brunt Nonalcoholic steatohepatitis: definition and pathology Semin Liver Dis 21 2001 3 16
17. P. Cacoub, F. Carrat, P. Bedossa, J. Lambert, G. Penaranda, and S. Pol Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study Antivir Ther 14 2009 839 845
18. Ryan P, Resino S, Miralles P, Cosin J, Lopez J, Moreno S, et al. Insulin resistance impairs sustained virologic response to interferon plus ribavirin in HIV/HCV-co-infected patients. CROI 2009, Montreal [abstract #843].
19. P. Nasta, F. Gatti, M. Puoti, G. Cologni, V. Bergamaschi, and F. Borghi Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a AIDS 22 2008 857 861
20. J.A. Mira, B. Valera-Bestard, A. Arizcorreta-Yarza, M. Gonzalez-Serrano, J. Torre-Cisneros, and I. Santos Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients Antivir Ther 12 2007 523 529 (Pubitemid 47041151)
21. N. Merchante, I. de los Santos-Gil, D. Merino, M. Gonzalez-Serrano, J.A. Mira, and J. Sanz-Sanz Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients J Hepatol 50 2009 684 692
22. M. Romero-Gomez, M. Diago, R.J. Andrade, J.L. Calleja, J. Salmeron, and C.M. Fernandez-Rodriguez Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin Hepatology 50 2009 1702 1708
23. M. Khattab, M. Emad, A. Abdelaleem, M. Eslam, R. Atef, and Y. Shaker Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance Liver Int 30 2010 447 454
24. K. Overbeck, D. Genne, A. Golay, F. Negro On behalf of the Swiss Association for the Study of the Liver (SASL) Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin J Hepatol 49 2008 295 298
25. N. Chand, K. Comar, and Mirshani. Fea Hyperinsulinemia blocks the inhibition of hepatitis C (HCV) replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV, nonalcoholic fatty liver disease Hepatology 40 2004 179A
26. K.A. Kim, W. Lin, A.W. Tai, R.X. Shao, E. Weinberg, and C.B. De Sa Borges Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection J Hepatol 50 2009 705 711
27. H. Miyaaki, T. Ichikawa, K. Nakao, T. Matsuzaki, T. Muraoka, and T. Honda Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C Hepatol Res 39 2009 850 855
28. M. Persico, M. Capasso, E. Persico, M. Svelto, R. Russo, and D. Spano Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy Hepatology 46 2007 1009 1015
29. T. Kawaguchi, T. Yoshida, M. Harada, T. Hisamoto, Y. Nagao, and T. Ide Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3 Am J Pathol 165 2004 1499 1508
30. J.G. Bode, S. Ludwig, C. Ehrhardt, U. Albrecht, A. Erhardt, and F. Schaper IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3 FASEB J 17 2003 488 490
31. P. Ryan, J. Berenguer, D. Michelaud, P. Miralles, J.M. Bellon, and E. Alvarez Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients J Acquir Immune Defic Syndr 50 2009 109 110
32. C. Camma, S. Bruno, V. Di Marco, D. Di Bona, M. Rumi, and M. Vinci Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C Hepatology 43 2006 64 71
33. L. Fartoux, O. Chazouilleres, D. Wendum, R. Poupon, and L. Serfaty Impact of steatosis on progression of fibrosis in patients with mild hepatitis C Hepatology 41 2005 82 87 (Pubitemid 40066385)
34. H.S. Conjeevaram, D.E. Kleiner, J.E. Everhart, J.H. Hoofnagle, S. Zacks, and N.H. Afdhal Race, insulin resistance and hepatic steatosis in chronic hepatitis C Hepatology 45 2007 80 87
35. E.J. Heathcote, M.L. Shiffman, W.G. Cooksley, G.M. Dusheiko, S.S. Lee, and L. Balart Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 2000 1673 1680
36. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)